Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2008 Sep;14(9):1017–1021. doi: 10.1016/j.bbmt.2008.06.013

Table 2.

Cumulative Incidence of Chronic GVHD

Chronic GVHD
N # with cGVHD 2 year cum inc (95% CI) P 2 year competing risk (95% CI) P
Total 98 53 54% (43–65%) 27% (18–36%)
 Placebo 31 17 55% (35–75%) 0.65 32% (16–48%) 0.26
67 36 53% (39–67%) 25% (15–35%)
Palifermin

The competing risks (death without chronic GVHD) are shown.